ArticleDrug delivery2017
Nanotechnology-based drug delivery of ropinirole for Parkinson's disease.
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis.Medicine · 2021Pooled it
- Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?Journal of Parkinson's disease · 2026Review
- Phosphatidylinositol-3-kinase/Protein Kinase B (PI3K/AKT) and Nucleotide-Binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 (NLRP3) Inflammasome Modulation Underlies the Neuroprotective Effects of Vildagliptin in a Rotenone-Induced Mouse Model of Parkinson's Disease.ACS pharmacology & translational science · 2026Article
- Ex Vivo Characterization and In Vivo Nasal Delivery of Ropinirole-Loaded PEO-b-PCL/Tween 80/β-Cyclodextrin Systems in C57BL/6J Mice.Molecules (Basel, Switzerland) · 2026Article
- Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery.Drug design, development and therapy · 2026Review
- Advanced P407/Tw80/βCD based Nasal Powders of Ropinirole Hydrochloride for Nose-to-Brain Delivery in Parkinson's Disease: Preparation and Comprehensive In Vitro and Ex Vivo Evaluation.The AAPS journal · 2025Article
- Intranasal delivery of rotigotine to the brain for treating Parkinson's disease.Fundamental research · 2025Article
- Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug delivery and translational research · 2025Review
- New nanomanufacturing strategy through bioinspired design, for promising treatment of Parkinson's disease.Scientific reports · 2025Article
- Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation.International journal of molecular sciences · 2024Article
- Article
- Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems.Pharmaceutics · 2022Review
- Nanoparticles in Drug Delivery: From History to Therapeutic Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Micro- and Nano-Systems Developed for Tolcapone in Parkinson's Disease.Pharmaceutics · 2022Article
- Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials.Nano-micro letters · 2022Review
- Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases.International journal of nanomedicine · 2022Review
- Targeting Oxidative Stress Mechanisms to Treat Alzheimer's and Parkinson's Disease: A Critical Review.Oxidative medicine and cellular longevity · 2022Review
- Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs.Pharmaceutics · 2021Review
- Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new drug delivery system is developed for ropinirole (RP) for the treatment of Parkinson's disease (PD) consisting of biodegradable poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). The formulation selected was prepared with 8 mg RP and 50 mg PLGA 502. This formulation exhibited mean encapsulation efficiency of 74.8 ± 8.2%, mean particle size lower than 155 nm, the zeta potential of -14.25 ± 0.43 mV and zero-order in vitro release of RP (14.13 ± 0.17 μg/h/10 mg NPs) for 5 d. Daily doses of the neurotoxin rotenone (2 mg/kg) given i.p. to male Wistar rats induced neuronal and behavioral changes similar to those of PD. Once neurodegeneration was established (15 d) animals received RP in saline (1 mg/kg/d for 35 d) or encapsulated within PLGA NPs (amount of NPs equivalent to 1 mg/kg/d RP every 3 d for 35 d). Brain histology and immunochemistry (Nissl-staining, glial fibrillary acidic protein and tyrosine hydroxylase immunohistochemistry) and behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that RP-loaded PLGA NPs were able to revert PD-like symptoms of neurodegeneration in the animal model assayed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.